Cover Image
市場調查報告書

日本的癌症治療藥開發平台分析

Japan Cancer Drug Pipeline Analysis

出版商 PNS Pharma 商品編碼 302556
出版日期 內容資訊 英文 557 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
日本的癌症治療藥開發平台分析 Japan Cancer Drug Pipeline Analysis
出版日期: 2014年01月14日 內容資訊: 英文 557 Pages
簡介

日本是亞太地區上癌症及相關醫藥品的一大市場。由於醫療服務的改善及癌症與治療相關認識的提升,成為推動日本研究活動增加的因素。

本報告提供日本的癌症治療藥開發平台的相關調查,提供藥物簡介概要,替代藥物的名字,起作用的適應症,開發階段,品牌名,專利資訊,及適應症·國家·不同組織的orphan指定等分析,為您概述為以下內容。

第1章 日本的癌症治療藥市場展望

第2章 癌症治療藥臨床開發階段:未確認

  • 概要
  • 臨床開發階段的癌症治療藥簡介

第3章 癌症治療藥臨床開發階段:研究

第4章 癌症治療藥臨床開發階段:前臨床

第5章 癌症治療藥臨床開發階段:臨床

第6章 癌症治療藥臨床開發階段:PhaseⅠ

第7章 癌症治療藥臨床開發階段:PhaseⅠ/Ⅱ

第8章 癌症治療藥臨床開發階段:PhaseⅡ

第9章 癌症治療藥臨床開發階段:PhaseⅡ/Ⅲ

第10章 癌症治療藥臨床開發階段:PhaseⅢ

第11章 癌症治療藥臨床開發階段:事前登記

第12章 癌症治療藥臨床開發階段:登記完畢

第13章 上市

圖表清單

目錄

Japan is a significant market for cancer and its related drugs in the Asia-Pacific region. Improved access to healthcare and an increased level of awareness about cancer and the options for its treatment have been major drivers for a rise in the research activities in this country.

With the strong continued support from the government, the Japanese cancer market is expected to grow rapidly in the future years. The government has been the major source of funding for cancer research in all these years. However, of late, many non-governing organizations have also started to support basic and clinical research. This increased trend of forming strategic partnerships would be a major driver of the industry. Additionally, Japan has taken many steps to improve the drug lag system. With the increasing inclusion of Japanese in the global Phase III trials, the drug lag situation is set to improve for many cancers like gastric, non-small cell lung, breast, colorectal, hepatocellular carcinoma, and chronic myelogenous leukemia.

Additionally, licensing agreements are increasingly being used in this market and these have proved to be more efficient from both a strategic and financial point of view in the cancer market in Japan. There would a high upfront values and low development milestones in the form of high probability of approvals in the licensing deals made at a late stage. This is extremely beneficial from a strategic point of view, for the pharma companies in their every-day decision making.

"Japan Cancer Drug Pipeline Analysis" by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of various cancers. Research report covers all drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Japan cancer drug market based upon development process.

Following parameters for each drug profile in development phase are covered in "Japan Cancer Drug Pipeline Analysis" research report:

  • Drug Profile Overview
  • Alternate Names for Drug
  • Active Indication
  • Phase of Development
  • Mechanism of Action
  • Brand Name
  • Patent Information
  • Orphan Designation by Indication, Country & Organisation
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class * ATC Codes

Number of Cancer Drugs in Pipeline by Clinical Phase:

  • Research: 23
  • Preclinical: 67
  • Clinical: 3
  • Phase-I: 98
  • Phase-I/II: 15
  • Phase-II: 26
  • Phase-II/III: 3
  • Phase-III: 37
  • Preregistration: 8
  • Registered: 8
  • Marketed: 90
  • Unknown: 1

Table of Contents

1. Japan Cancer Drug Market Overview

2. Cancer Drug Clinical Development Phase: Unknown

  • 2.1. Overview
  • 2.2. Cancer Drug Profile in Clinical Development Phase

3. Cancer Drug Clinical Development Phase: Research

  • 3.1. Overview
  • 3.2. Cancer Drug Profile in Clinical Development Phase

4. Cancer Drug Clinical Development Phase: Preclinical

  • 4.1. Overview
  • 4.2. Cancer Drug Profile in Clinical Development Phase

5. Cancer Drug Clinical Development Phase: Clinical

  • 5.1. Overview
  • 5.2. Cancer Drug Profile in Clinical Development Phase

6. Cancer Drug Clinical Development Phase: Phase-I

  • 6.1. Overview
  • 6.2. Cancer Drug Profile in Clinical Development Phase

7. Cancer Drug Clinical Development Phase: Phase-I/II

  • 7.1. Overview
  • 7.2. Cancer Drug Profile in Clinical Development Phase

8. Cancer Drug Clinical Development Phase: Phase-II

  • 8.1. Overview
  • 8.2. Cancer Drug Profile in Clinical Development Phase

9. Cancer Drug Clinical Development Phase: Phase-II/III

  • 9.1. Overview
  • 9.2. Cancer Drug Profile in Clinical Development Phase

10. Cancer Drug Clinical Development Phase: Phase-III

  • 10.1. Overview
  • 10.2. Cancer Drug Profile in Clinical Development Phase

11. Cancer Drug Clinical Development Phase: Preregistration

  • 11.1. Overview
  • 11.2. Cancer Drug Profile in Clinical Development Phase

12. Cancer Drug Clinical Development Phase: Registered

  • 12.1. Overview
  • 12.2. Cancer Drug Profile in Clinical Development Phase

13. Marketed

  • 13.1. Overview
  • 13.2. Marketed Cancer Drug Profile

List of Table

Each Drug Profile has Tables Representing Following Information:

  • Alternate Names
  • Originator & Owner
  • Collaborator
  • Technology Provider
  • Licensee
  • Highest Development Phase
  • Indications
  • Class
  • Mechanism of Action
  • ATC Code
  • Designated Brand Name
Back to Top